Yuyu's Maxmavil Receives U.S. Patent

Yuyu announced on January 10th that it has received the U.S. patent for Maxmavil, a novel combination anti-osteoporosis drug formulated with alendronate and calcitrol.

Maxmavil is the first novel combination drug by the domestic pharmaceutical industry, where it obtained the marketing approval by the Korea Food and Drug Administration (KFDA) back in November of last year, and the company pla...